Name: Latest research reports of Alivus Life Sciences Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Alivus Life Sciences Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Alivus Life Sciences Ltd.

NSE: ALIVUS | BSE: 543322 | ISIN: INE03Q201024 | Industry: Pharmaceuticals
| Mid-range Performer

1063.3000 -2.90 (-0.27%)

NSE Jul 17, 2025 10:52 AM

29.82% Gain from 52W Low

Volume: 94,057

Alivus Life Sciences Ltd.

29 Apr 2023

1063.30

-0.27%

Glenmark Life Sciences (BUY): All-round beat

Buy: Alivus Life Sciences Ltd.

Target

BOB Capital Markets Ltd.

Q4 revenue of Rs 6.2bn (+21% YoY) beat our estimate by 14% driven by recovery in CDMO and growth in API

Alivus Life Sciences.. has an average target of 1152.00 from 2 brokers.